July 14, 2020
Veryan Medical Will Support Commercialization of Walk Vascular’s Jeti Thrombectomy System in Germany
July 14, 2020—Walk Vascular, LLC and Veryan Medical have announced that Veryan Medical will support Walk Vascular in the commercialization of the Jeti peripheral thrombectomy system in Germany.
The currently commercialized, CE Mark–approved and FDA-cleared Jeti catheters are indicated for the break-up and removal of clot within the peripheral vasculature and are used to treat patients with peripheral arterial occlusions and deep vein thrombosis.
According to Walk Vascular, the Jeti thrombectomy system employs an internal jet and is intended to remove/aspirate fluid and break-up soft emboli and thrombus from the peripheral vasculature and to subselectively infuse/deliver diagnostics or therapeutics with or without vessel occlusion. The device is capable of engaging large thrombus volumes through a miniature lumen, rapidly clearing peripheral vessels that can often prove challenging for standard aspiration devices.
Walk Vascular is headquartered in Irvine, California. Veryan, based in Horsham, United Kingdom, became an Otsuka Medical Devices company in December 2018.
David Look, President and CEO of Walk Vascular, commented in the announcement, “By working with Veryan Medical we can hit the ground running. Veryan provides an invaluable catalyst to our commercial efforts, providing access to key opinion leaders in Germany through an experienced sales team with clinical expertise.”